CVS and Cigna Under Fire for Anticompetitive PBM Practices
Tuesday, 1 October 2024, 18:26
CVS and Cigna’s Anticompetitive Strategies
CVS (CVS) and Cigna (CI) have come under scrutiny from Congress regarding their new anticompetitive practices. Lawmakers are challenging the tactics employed by their Pharmacy Benefit Managers (PBMs), which merge operations in a way that raises questions about market health.
Potential Impact on Consumers
- Consumer costs may rise as competition weakens.
- This development could result in fewer choices for patients needing medications.
- Regulatory bodies are investigating these claims closely.
Industry Reactions
- Pharmaceutical lobbyists are speaking out.
- Consumer advocacy groups are rallying against these practices.
- Investors are monitoring the situation for financial repercussions.
Industry experts predict that if these practices go unchallenged, CVS and Cigna may set a concerning precedent in the pharmaceutical sector. Stakeholders are urged to pay attention to these developments as they unfold.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.